Abstract
The most important radioisotope for use in Nuclear Medicine is 99mTc, supplied in the form of a 99Mo/99mTc generator. After the supply crisis of 99Mo starting in 2008 the availability of 99Mo became a worldwide concern. The purpose of this work is to do a brief story of the availability of 99Mo in the world followed by an overview of the production routes of 99Mo and the generators technology.
Keywords: Fission of 235U, Molybdenum-99, Nuclear Reactor, Particle Accelerator, Radioisotope generator, Technetium-99m, HEU, LEU, GTRI/DOE efforts
Current Radiopharmaceuticals
Title:Technetium-99m – New Production and Processing Strategies to Provide Adequate Levels for SPECT Imaging
Volume: 5 Issue: 3
Author(s): J. A. Osso, M. F. Catanoso, G. Barrio, T. P. Brambilla, R. Teodoro, C. R. B. R. Dias and K. N. Suzuki
Affiliation:
Keywords: Fission of 235U, Molybdenum-99, Nuclear Reactor, Particle Accelerator, Radioisotope generator, Technetium-99m, HEU, LEU, GTRI/DOE efforts
Abstract: The most important radioisotope for use in Nuclear Medicine is 99mTc, supplied in the form of a 99Mo/99mTc generator. After the supply crisis of 99Mo starting in 2008 the availability of 99Mo became a worldwide concern. The purpose of this work is to do a brief story of the availability of 99Mo in the world followed by an overview of the production routes of 99Mo and the generators technology.
Export Options
About this article
Cite this article as:
A. Osso J., F. Catanoso M., Barrio G., P. Brambilla T., Teodoro R., R. B. R. Dias C. and N. Suzuki K., Technetium-99m – New Production and Processing Strategies to Provide Adequate Levels for SPECT Imaging, Current Radiopharmaceuticals 2012; 5 (3) . https://dx.doi.org/10.2174/1874471011205030178
DOI https://dx.doi.org/10.2174/1874471011205030178 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Introduction (Transient Receptor Potential TRP Channels as Therapeutic Drug Targets: Next Round!)
Current Topics in Medicinal Chemistry MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Extracellular Citrate in Health and Disease
Current Molecular Medicine Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Role of Natural Compounds Against Skin Aging
Current Medicinal Chemistry Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview
Current Pharmaceutical Design Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Current Cancer Drug Targets Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry